Squarepoint
VECT

Squarepoint’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Squarepoint’s Portfolio VECT Stock Details VECT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$193K – 3638
2021
Q3 		$193K Hold
25,000
– – ﹤0.01% 2506
2021
Q2 		$292K Buy
+25,000
New +$380K ﹤0.01% 2552

Other funds holding VECT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's VECT Position: Q4 2021 in Review

Squarepoint sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q4 2021, closing a stake of 25,000 shares — an estimated $193K sold.

Squarepoint first reported a position in VECT in Q2 2021 and held it in 2 quarters. The position peaked at $292K in Q2 2021. 21 funds tracked by Wall St. Rank hold VECT as of Q4 2021.

  • Squarepoint reported no remaining VectivBio Holding AG Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • Squarepoint sold 25,000 VectivBio Holding AG Ordinary Shares shares in Q4 2021, an estimated $193K.
  • Squarepoint first reported a position in VectivBio Holding AG Ordinary Shares in Q2 2021 and held it in 2 quarters.
  • Squarepoint's VectivBio Holding AG Ordinary Shares position peaked at $292K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.